Vaxart, Inc.

117 articles about Vaxart, Inc.

• Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

  3/27/2024

  Vaxart, Inc. announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024.

• Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  3/20/2024

  Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024.

• Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

  3/14/2024

  Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.

• Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

  3/7/2024

  Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024.

• Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

  3/6/2024

  Vaxart, Inc. announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024.

• Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

  2/5/2024

  Vaxart, Inc. announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s.

• Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

  1/19/2024

  Vaxart, Inc. (Nasdaq: VXRT) today announced that the United States Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company $9.27 million to fund preparation for a 10,000 subject Phase 2b clinical study evaluating Vaxart’s oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator.

• Vaxart, Inc. Announces Management Change - Jan 16, 2024

  1/16/2024

  Vaxart, Inc. announced a change in management. Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with Vaxart as President, Chief Executive Officer, and Director on Vaxart’s Board of Directors.

• Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

  1/16/2024

  Vaxart, Inc. announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.

• Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

  12/21/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

• Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

  11/2/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2023.

• Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

  11/2/2023

  Vaxart, Inc. announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

• Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

  10/26/2023

  Vaxart, Inc. announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on Thursday, November 2, 2023.

• Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

  10/11/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.

• Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

  9/21/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET.

• Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

  9/6/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced top-line data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate (NCT05212168).

• Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

  8/3/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the second quarter of 2023.

• Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

  7/27/2023

  Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023.

• Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

  7/6/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.

• Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

  6/26/2023

  Vaxart, Inc. held its Annual Meeting of Shareholders in a virtual-only format.